Objective To study the effect of menglusite combined with compound ipratropium bromide solution for aerosol inhalation treatment of cough in children after infection .Methods Total of 74 children with cough after infection in Beijing Fengtai hospital from Apr .2014 to Mar.2014 were included in the study, according to the random number table method they were divided into an observation group and a control group,37 cases each.The control group was given menglusite dulcet,4 mg/d for the 1-5 years old, 5 mg/d for the 6-10 years old,once a day;the observation group was added compound ipratropium bromide solution for atomization inhalation on the basis of the control group′s regimen, atomization inhalation,2 times a day,and the treatment course was 10 days.The cough score changes before and after treatment,clinical symptoms disappearing time ,clinical curative effect and adverse reaction of the two groups were observed and compared.Results After 5, 10 d of treatment the cough score of both groups was in a downward trend,and the observation group was falling faster[observation group:(2.01 ±0.33) point,(1.03 ±0.14)point vs (2.51 ±0.48)point;control group:(1.47 ±0.21) point,(0.31 ±0.05) point vs (2.51 ±0.48) point], the differences between groups,time points,groups・ time points interaction were statistically significant ( P<0.05 ) .Cough symptoms relief and disappearing time of the observation group were shorter than the control group[(6.4 ±1.2) d, (8.4 ±2.1) d vs (8.9 ±2.2) d, (11.0 ±3.0) d], the differences were statisti-cally significant(P<0.01).The total effective rate of the observation group was higher than the control group [91.89% (34/37) vs 70.27% (26/37)] (P<0.05).Adverse reaction rate of the two groups had no statistically significant difference [ 2.70% ( 1/37 ) vs 5.41% ( 2/37 ) ] (χ2 =0.3474 , P >0.05 ) . Conclusion Menglusite joint compound ipratropium bromide solution for aerosol inhalation treatment of child cough after infection ,can effectively shorten the clinical symptoms relief and disappearing time ,with good clinical curative effect and high safety.%目的：研究孟鲁司特口服联合吸入用复方异丙托溴铵溶液雾化吸入治疗儿童感染后咳嗽的临床疗效。方法选择2013年4月至2015年3月北京丰台医院收治的感染后咳嗽患儿74例，按照随机数字表法分为观察组和对照组，各37例。对照组口服孟鲁司特钠咀嚼片，1～5岁剂量为4 mg／d，6～10岁剂量为5 mg／d，每日1次；观察组在此基础上联合吸入用复方异丙托溴铵溶液雾化吸入，每日2次，疗程均为10 d。比较两组患儿治疗前后咳嗽评分变化，观察两组患儿临床症状消失时间、临床疗效和不良反应发生情况。结果两组患儿治疗5、10 d咳嗽评分均较治疗前呈下降趋势，观察组在治疗5、10 d的下降速度更快[观察组：（2．01±0．33）分、（1．03±0．14）分比（2．51±0．48）分；对照组：（1．47±0．21）分、（0．31±0．05）分比（2．51±0．48）分]，两组在组间、不同时点间、组间・不同时点间交互作用比较差异有统计学意义（ P ＜0．05）。观察组患儿的咳嗽症状缓解时间和消失时间显著短于对照组[（6．4±1．2） d比（8．9±2．2） d、（8．4±2．1） d 比（11．0±3．0） d]，差异有统计学意义（ P＜0．01）。观察组患儿总的有效率显著高于对照组[91．89％（34／37）比70．27％（26／37）]（P＜0．05）。两组不良反应发生率比较差异无统计学意义[2．70％（1／37）比5．41％（2／37）]（χ2＝0．3474，P＞0．05）。结论孟鲁司特口服联合吸入用复方异丙托溴铵溶液雾化吸入治疗儿童感染后咳嗽，能缩短患儿的临床症状缓解时间和消失时间，临床疗效良好，安全性高。
展开▼
